SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-21-000016
Filing Date
2021-02-11
Accepted
2021-02-11 16:07:45
Documents
15
Period of Report
2021-02-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rare-20210211.htm   iXBRL 8-K 41354
2 EX-99.1 rare-20210211-ex99_1.htm EX-99.1 174691
3 GRAPHIC img44466235_1.jpg GRAPHIC 375412
4 GRAPHIC img44466235_0.jpg GRAPHIC 375412
  Complete submission text file 0000950170-21-000016.txt   1375361

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT rare-20210211.xsd EX-101.SCH 2249
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT rare-20210211_lab.xml EX-101.LAB 12931
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT rare-20210211_pre.xml EX-101.PRE 9590
8 EXTRACTED XBRL INSTANCE DOCUMENT rare-20210211_htm.xml XML 4522
Mailing Address 60 LEVERONI COURT NOVATO CA 94949
Business Address 60 LEVERONI COURT NOVATO CA 94949 415-483-8800
Ultragenyx Pharmaceutical Inc. (Filer) CIK: 0001515673 (see all company filings)

IRS No.: 272546083 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36276 | Film No.: 21619686
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences